Current Projects
Tuberculosis Trials Consortium Clinical Research Services (TBTC)
A CDC-funded project to support clinical trials and clinical research on the treatment, diagnosis and prevention of tuberculosis.
Higher Dose Rifampin for two Months vs Standard Dose Rifampin for Latent TB
A clinical study designed to determine if two months of daily treatment of Rifampin at double or triple the standard dose is non-inferior for safety and superior for completion as the standard dose of Rifampin when taken for four months to treat latent TB.
GeneXpert or chest x-rays or tuberculin testing for household contact assessment – a cluster randomized trial
The objective of the study is to compare outcomes from three different strategies for the management of household contacts of individuals with newly diagnosed microbiologically confirmed active pulmonary TB.
Past Projects
Cost-effectiveness of TB screening in Nunavik
We assessed the cost-effectiveness of active screening in the presence of varying outbreak frequency and intensity. We also considered scenarios involving variation in timing, impact and uptake of screening programs.
Enhancing the public health impact of latent TB infection diagnosis and treatment: A pragmatic cluster randomized trial
A pragmatic cluster randomized trial to assess a new rapid and standardized approach to improving TB prevention. We have identified sites in Canada, Benin, Brazil, Ghana, Indonesia and Vietnam to conduct this study, with the objective of expanding this approach throughout these countries.
A randomized clinical trial of four months Rifampin vs. nine months Isoniazid for latent TB infection (Phase 3 effectiveness)
To compare the cumulative incidence of confirmed active TB during 28 months after randomization between four months of daily Rifampin to nine months of daily Isoniazid.
Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis
Using a rich date base of patient records, we addressed important questions regarding interpretation of drug susceptibility testing, the role of surgery, prognosis and correlates of treatment success in drug resistant TB, generating five papers and influencing WHO recommendations.
